The Current Ratio as of November 2024 (TTM) for Halozyme Therapeutics, Inc. (HALO) is 10.36

According to Halozyme Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 10.36. This represents a change of 33.48% compared to the average of 7.76 of the last 4 quarters.

Halozyme Therapeutics, Inc. (HALO) Historical Current Ratio (quarterly & annually)

How has HALO Current Ratio performed in the past?

The mean historical Current Ratio of Halozyme Therapeutics, Inc. over the last ten years is 4.87. The current 10.36 Current Ratio has changed 21.17% with respect to the historical average. Over the past ten years (40 quarters), HALO's Current Ratio was at its highest in in the June 2020 quarter at 19.19. The Current Ratio was at its lowest in in the December 2020 quarter at 1.32.

Halozyme Therapeutics, Inc. (HALO) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Halozyme Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Halozyme Therapeutics, Inc. (HALO) Average Current Ratio

How has HALO Current Ratio performed in the past?

The current Current Ratio of Halozyme Therapeutics, Inc. (HALO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Halozyme Therapeutics, Inc. (HALO) Current Ratio vs. Peers

How is HALO’s Current Ratio compared to its peers?

Halozyme Therapeutics, Inc.’s Current Ratio is greater than Agios Pharmaceuticals, Inc. (8.99), greater than Insmed Incorporated (6.37), greater than Cerevel Therapeutics Holdings, Inc. (10.22), greater than Ultragenyx Pharmaceutical Inc. (2.81), greater than BioMarin Pharmaceutical Inc. (4.27), greater than Seagen Inc. (2.67), greater than Alnylam Pharmaceuticals, Inc. (2.75), greater than Exelixis, Inc. (3.93), greater than Alector, Inc. (3.29), greater than Legend Biotech Corporation (4.98), greater than Ascendis Pharma A/S (1.16), greater than Cytokinetics, Incorporated (9.28), less than Edgewise Therapeutics, Inc. (26.35), greater than Apellis Pharmaceuticals, Inc. (4.36), greater than Blueprint Medicines Corporation (3.32), greater than BeiGene, Ltd. (1.93), greater than Inhibrx Biosciences, Inc. (4.70), less than Protagonist Therapeutics, Inc. (10.70), less than DICE Therapeutics, Inc. (38.14), less than Larimar Therapeutics, Inc. (13.10), less than Viridian Therapeutics, Inc. (18.55),

Build a custom stock screener for Halozyme Therapeutics, Inc. (HALO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Halozyme Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Halozyme Therapeutics, Inc. (HALO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Halozyme Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.